Jumo Health secures funding to improve clinical trial enrollment –

What you need to know:

– Falfurrias Management Partners (Falfurrias), a Charlotte-based private equity firm focused on growth-oriented middle market companies, today announced its investment in Jumo Health, an innovative, award-winning clinical research solutions company that is driving better clinical trial outcomes globally.

– Jumo Health develops creative, patient-centric educational solutions that improve health literacy to accelerate clinical trial enrollment and increase participant retention.

Falfurrias Capital Partners invests in Jumo Health to improve inclusion and diversity in clinical trials

Falfurrias Capital Partners announced an investment in Jumo Health, with the goal of addressing critical challenges in clinical trials, such as low enrollment, high dropout rates, and lack of diverse representation. This strategic investment will bring new resources and expertise to Jumo Health, enhance core capabilities, enable data-driven solutions, and increase patient engagement.

Key aspects of the partnership include:

– Focus on Diversity and Inclusion: Jumo Health is committed to improving access to clinical trials for underrepresented communities. Jumo Health recognizes the deep-seated distrust these groups may have of the healthcare system due to historical inequities and has taken concrete steps to rebuild trust by:

– Creating culturally sensitive educational materials tailored to the age, gender, race, language, and socioeconomic status of participants.

– Establishing a strong network of more than 2,000 religious, social, government and community organizations, as well as patient advocacy organizations.

– Clinical Trial Impact: Jumo Health’s curriculum-based educational solutions ensure that potential clinical trial participants receive relevant information at every stage of their journey, from pre-consent trial awareness to ongoing engagement. The result is:

– Faster recruitment

– Longer retention

– Increased patient compliance

– Greater overall trial success for sponsors

– Leadership and Governance: The investment includes key leadership appointments to the Jumo Health Board of Directors:

– Adam Cossman, with 25 years of experience in pharmaceutical commercialization, will assume the role of Chairman.

– Alexander Jutkowitz, a global expert in content marketing and communications, and Jackie Kent, a pharmaceutical executive with nearly 30 years of experience in clinical trial innovation, will also join the board of directors.

This investment, from Falfurrias Capital Partners V, a lower middle market buyout fund with an operational focus, builds on Falfurrias’ extensive experience in marketing and communications. Houlihan Lokey represented Falfurrias in the transaction, with legal counsel provided by Holland & Knight. Jumo Health was represented throughout the process by Canaccord Genuity LLC.

“Treatment developments for increasingly targeted patient populations depend on more diverse and innovative clinical research solutions,” said Adam Cossman. “As treatments become more personalized and trials become more complex, the need for effective patient communication has never been more important. Jumo Health’s patient-centric approach goes to the heart of these issues, and we look forward to helping them achieve their mission.”